MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
- 10 January 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (6) , 948-956
Abstract
Proteolysis-targeting chimeras (PROTAC) are bivalent molecules that simultaneously bind to proteins of interest and cellular ubiquitin E3 ligases to promote target degradation. Tumor-specific expression of E3 should increase therapeutic efficacy and reduce toxicity in cancer therapy applications. The E3 ligases currently employed during PROTAC design, such as CRBN, VHL, c-IAP, and MDM2, are ubiquitously expressed and not considered tumor-specific. However, MDM2 is part of the p53-negative feedback loop and is dynamically regulated at transcriptional and posttranslational levels. MDM2 gene amplification occurs at a frequency of 4% to 20% in multiple tumor types. To investigate whether MDM2 can serve as a tumor-specific PROTAC E3 in certain settings, we analyzed the benchmark compound A1874 (JQ1-Idasanutlin chimera targeting BRD4) under various conditions that affect MDM2 expression and activity. The results showed that A1874 activity is dependent on p53-mediated induction of MDM2 expression and is inactive in cells with mutant p53. Importantly, A1874 showed, on average, ∼12-fold higher potency in tumor cells with MDM2 amplification compared with nonamplified cells, correlating with enhanced cytotoxicity. The results suggest that tumors with MDM2 amplification or overexpression can be selectively targeted using the PROTAC approach.Keywords
All Related Versions
Funding Information
- National Institutes of Health (CA141244)
- National Institutes of Health (CA260356)
- National Institutes of Health (CA279378)
- Florida Department of Health (20B17)
- National Institutes of Health (P30-CA076292 (Moffitt Cancer Center & Research Institute))
This publication has 34 references indexed in Scilit:
- A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis inductionBiochemical and Biophysical Research Communications, 2023
- Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphomaBioorganic Chemistry, 2023
- Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancerEuropean Journal of Medicinal Chemistry, 2022
- Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to ClinicChemBioChem, 2021
- Targeting pan-essential genes in cancer: Challenges and opportunitiesCancer Cell, 2021
- Design and synthesis of selective degraders of EGFRL858R/T790M mutantEuropean Journal of Medicinal Chemistry, 2020
- Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic DependenciesCancer Cell, 2017
- The ARF tumor suppressor: Structure, functions and status in cancerInternational Journal of Cancer, 2010
- Signaling to p53: Ribosomal Proteins Find Their WayCancer Cell, 2009
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomicsBioorganic & Medicinal Chemistry Letters, 2008